Saturday 17 October 2026
Export VALN’s income statement to Excel — free account
Valneva SE Sponsored ADR
VALN Healthcare Biotechnology
In the quarter to June 2026, revenue fell 17.3%, EPS fell 222.1%, free cash flow fell 56.1% and total debt rose 12.1%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
5.61
0.30
−5.08%
Follow VALN
| Jun '26 | Mar '26 | Sep '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | 66.49 | — | — |
+8 more quarters Free account |
P/S ratio |
— | 3.39 | — | — | |
P/FCF ratio |
— | 0.00 | — | — | |
P/Operating CF |
— | (1,520.13) | — | — | |
P/B ratio |
— | 6.20 | — | — | |
Price to Tangible BV |
— | 8.64 | — | — | |
EV/Sales |
— | 3.94 | — | — | |
EV/EBITDA |
— | 48.49 | — | — | |
EV/Operating CF |
— | (14.08) | — | — | |
EV/FCF |
— | (12.16) | — | — | |
Quick Ratio |
1.33 | 1.22 | 1.09 | 1.48 | |
Current Ratio |
2.16 | 2.14 | 1.78 | 2.27 | |
Net Debt/EBITDA |
0.00 | (3.25) | 0.00 | 0.00 | |
Debt/Assets |
47.40% | 49.01% | 37.42% | 35.63% | |
Debt/Equity |
2.27 | 2.38 | 1.11 | 0.90 | |
Asset Turnover |
0.00 | 0.33 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 0.01 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
— | (4.65) | — | — | |
Research and Development Expense of Revenue |
— | 49.23% | — | — | |
Selling, General and Administrative Expense of Revenue |
— | 48.98% | — | — | |
Intangible Assets out of Total Assets |
0.05 | 0.06 | 0.05 | 0.05 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | — | 0.00% | |
Graham Net Nets |
— | (0.20) | — | — | |
Graham Number |
— | 1.46 | — | — | |
Earnings Yield |
— | 1.50% | — | — | |
Free Cash Flow Yield |
— | (9.56%) | — | — | |
Revenue per Share |
— | 0.41 | — | — | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | (0.01) | 0.00 | 0.00 | |
Cash per Share |
0.00 | 1.38 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 1.01 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 1.01 | 0.00 | 0.00 | |
Free Cash Flow |
(15.82) | (0.66) | (37.06) | (5.36) | |
Working Capital |
139.00 | 125.49 | 137.75 | 180.56 | |
Capital Expenditures |
(0.20) | (0.29) | (3.88) | (1.52) | |
Net Current Asset Value |
(97.99) | (109.87) | (34.39) | (1.68) | |
EV/EBIT |
— | 29.08 | — | — | |
Capex to Sales |
0.00 | 0.01 | 0.00 | 0.00 | |
Price to Operating Income |
— | 25.02 | — | — | |
| Other line items | |||||
Average Receivables |
27.16 | 22.62 | 28.17 | 28.50 | |
Average Payables |
27.98 | 36.35 | 35.18 | 30.17 | |
Average Inventory |
60.49 | 61.40 | 63.89 | 61.41 | |
Average Assets |
479.75 | 501.74 | 513.19 | 541.22 | |
Average Common Equity |
139.47 | 164.45 | 177.48 | 208.54 |
Columns are period end dates